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INTRODUCTION 
There is no doubt that in recent years, dry eye disease has become an 
extremely common condition that causes varying degrees of ocular discomfort and 
disability. Information on dry eye disease is limited due lack of uniformity in its 
definition and the inability of any single diagnostic test or set of diagnostic tests to 
confirm or rule out the condition. Thus, there has been a shift towards symptom-
based assessment as the key component of clinical diagnosis. 
Reported prevalence of dry eye in the literature is diverse: ranging between 
7.8% in one study from western world and 93.2% in one study from Asia. This is 
probably because of two factors: first, the geographical location of the study 
population and secondly, there is no standardization of the selected population, dry 
eye questionnaires, objective tests and dry eye diagnostic criteria.  
According to studies conducted in Northern and Eastern India, the 
prevalence of dry eye was found to be between 18.4 and 40.8%. One small study 
from Leh showed a higher prevalence of dry eye of 54% in high altitude.   
Dry eye syndrome is a chronic disease becoming commoner among the 
people all over the world, some of whom become blind as sequelae. Added to the 
systemic factors, drugs and environment alter the characteristics of the tear film, 
which is indispensable for a healthy ocular surface.  
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So a better knowledge of this disease and better mode of treatment would aid 
the physician to help these patients to overcome this chronic, plaguing problem and 
maintain a good visual acuity and comfort for the rest of their life and thereby 
ensure a better living condition of these patients with this incurable disease. 
Anti-psychotic agents are very commonly used medications in a Psychiatry 
setup for patients suffering from Psychoses and Delusional disorder. As these 
patients are on medications all through their life , side effects are seen very 
commonly in them. Liver is the organ most commonly affected by Anti-psychotic 
medications, followed by eyes. Ocular side effects include blurring of vision, dry 
eye, corneal deposition of drugs, stellate capsular deposits, oculo-gyric crisis etc. 
Of these many ocular side effects, Dry eye disease, often does not get proper 
attention and thus, leads to great discomfort to the patients.  
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                                   NEED FOR STUDY 
DRY EYE IN PATIENTS ON ANTI-PSYCHOTIC THERAPY 
Antipsychotics have a significant dose related anticholinergic side effect 
leading to symptoms like dry mouth, blurring of vision, urinary hesitancy. Another 
significant side effect is dry eye which is often neglected leading to great 
discomfort to the patient.  
Possible mechanism  suggested is – Due to the anti-cholinergic action of 
these drugs, they block the muscarinic receptors present over lacrimal gland . This 
decreases the tear secretion leading to an unstable tear aqueous layer. And that is 
the reason for  aqueous deficiency and dryness of eyes. 
According to a study by Mcintosh et al, the schizophrenic patients on 
neuroleptics showed decreased blink rate which may be another cause of dry eye in 
these patients.6 
Our study aims at dealing with this particular side effect of the Anti-
psychotic agents. 
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                                HISTORICAL REVIEW 
      YEAR      DEVELOPMENT 
5TH-4TH BC 
Ophthalmic conditions were classified as dry or humid by 
Hippocrates 
1888 The term xerostomia was introduced by Hadden 
1892 Mikulicz syndrome was described by Mikulicz 
1930 
The term keratoconjunctivitis Sicca was first used by 
Henrique Sjogren 
1936 
Keratoconjunctivitis Sicca was named as Sjogrens 
syndrome by Duke Elder 
1946 
Three –layered tear film structure concept was presented 
by Wolff 
1995 
The National eye institute /industry(NEI/Industry)Dry 
Eye Workshop classifications 
1998 
Michael Stern proposed that cytokine/receptor-mediated 
inflammation is common to all ocular surface disorders 
including Dry eye 
2005 Triple classification by Juan Murube 
2006 Delphi approach to treatment recommendation 
2007 International Dry Eye Workshop(DEWS)report 
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ANATOMY OF TEAR FILM 
The term PRE-CORNEAL TEAR FILM was given by Wolff. It has got 3 
layers: 
1) LIPID LAYER: It is the outermost superficial oily layer. It is derived from 
secretions of meibomian, zeiss and moll glands. It forms the marginal tear strips. 
Lipids of low polarity like wax, cholesterol are fluid at body temperature. The high 
polarity lipids are negligible and constitutes of triglycerides, free fatty acids and 
phospholipids. Thickness of this layer is 0.1um, which increases when lids are 
partially closed. It prevents the overflow of tears and retards the evaporation. 
2) AQUEOUS LAYER: It is  the middle layer. It is secreted by the main 
lacrimal gland and accessory glands of krausse and wolffring. Its thickness is 
10um.It forms an aqueous solution of low viscosity containing ions of organic 
salts, urea, glucose,  biolpolymers such as enzymes, proteins and glycoproteins 
with proteins like lysozyme, lactoferrin, tear specific prealbumin, secretory 
immunoglobulin A. It has a buffering action due to bicarbonate and proteins 
present in it. It is rich in surface active substances like mucus glycoproteins which 
helps in reducing surface tension. It provides atmospheric oxygen to epithelium, 
washes away debris and notoriuous irritants, contains anti bacterial substances like 
lysozyme and betalysin. 
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3) MUCIN LAYER: It is the deepest layer which is produced by conjuctival 
goblet cells, crypts of henle and glands of manz. Also, by main lacrimal gland. It is 
responsible for the stability of the tear film with a thickness of 30 um (thickest 
according to the latest studies using confocal microscopy). The clear corneal 
surface is hydrophobic. Mucin gets absorbed on the surface of the epithelial cells 
and anchored by their microvilli forming hydrophobic surface on which aqueous 
and lipid layers spreads spontaneously .It lubricates ocular and palpebral surfaces 
leading to minimal friction during blinking and eye movements. It provides 
slippery surface over foreign body, and helps prevent abrasion formation. 
 
 
 
 
 
 
 
 
 
 
  
 
 
ANATOMY OF TEAR FILM 
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FUNCTIONS OF TEAR FILM 
* Forms a perfectly smooth optical surface on the cornea by filling in and 
smoothening out small surface irregularities in the corneal epithelium. 
* Keeps the surface of conjuctiva and cornea moist. 
* Acts as lubricant for pre-ocular surface and lids, decreasing frictional forces 
generated by blinking and eye movement. 
* Transfers oxygen from air to cornea. 
* Prevents infection due to the presence of antibacterial substances as 
lysozyme, betalysin, lactoferrin, immunoglobulins and other proteins in it. 
* Washes away debris and noxious irritants. 
* Gives a pathway to WBCs in case of injury. 
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DRY EYE DISEASE 
DEFINITION 
 
NEI definition (1995): Dry eye disease (DED) is a disorder of the tear film 
due to reduced tear production or excessive tear evaporation, which causes damage 
to the inter-palpebral ocular surface and is associated with symptoms of ocular 
discomfort and/ or visual symptoms. 
DEWS Definition (2007): Dry eye disease is a multifactorial disease of the 
tear film and ocular surface that results in symptoms of discomfort, visual 
disturbance, and tears film instability with potential damage to the ocular surface. 
It is accompanied by increased osmolality of tear film and inflammation of the 
ocular surface. 
SIGNIFICANCE OF THE NEW DEFINITION: The role of 
hyperosmolarity of tear film, inflammation of the ocular surface and effect on 
visual acuity found a place in the new definition which were not considered in 
previous definition. 
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PATHOGENESIS 
The lacrimal glands, ocular surface, lids, and the sensory and motor nerves 
that connect them, they all act as an integrated functional unit known as Lacrimal 
functional unit or LFU which maintains the tear production and helps to clear used 
tears. 
Any disease or dysfunction of this unit results in an unstable and poorly 
maintained tear film that leads to ocular irritation and ocular surface disease known 
as keratoconjunctivitis sicca (KCS). 
The dysfunction of this LFU may develop from natural aging, a decrease in 
supportive factors ( as androgen hormones), systemic inflammatory diseases (like 
rheumatoid arthritis), ocular surface diseases (as HSV keratitis) or surgeries which 
disrupt the afferent sensory nerves ( as in LASIK), and systemic diseases or 
medications that disrupt the efferent nerves that stimulate tear secretion. 
A decrease in tear secretion and clearance initiates an inflammatory response 
on the ocular surface that involves soluble and cellular pro-inflammatory mediators 
(cytokines). Research shows that T-cell lymphocytes also play a major role in the 
pathogenesis of KCS. 
   
                          
 
 
 
 
                                      
 
 
CLASSIFICATION 
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CLINICAL FEATURES 
   SYMPTOMS 
•  Feeling of dryness, grittiness and burning that worsens during day are the 
most common symptoms  
• Stringy discharge, transient blurring of vision, redness, paradoxical 
watering, photophobia  may be there. 
• The symptoms are usually exacerbated in conditions associated with 
increased tear evaporation (air-conditioning, wind and central heating) or 
prolonged reading which leads to reduced blink rate. 
Ocular history:  
       • Topical medications used and  their frequency like anti-histaminic, glaucoma 
medications, corticosteroids  
       • Contact lens use- type and wearing schedule 
       • Chronic allergic disease of the eye 
        • Ocular surgical history as prior keratoplasty, cataract surgery, refractive 
surgery ,prior lid surgeries 
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• Ocular surface disorder i.e. HSV infection, varicella zoster virus, OCP, SJS, 
aniridia, GVHD 
Medical history:  
• Menopause  
• Systemic inflammatory diseases i.e. Sjögren syndrome, rheumatoid arthritis, 
systemic lupus erythematosus 
• Atopy: e.g., dermatitis, rhinitis, bronchial asthma 
• Systemic medications i.e. antihistamines, diuretics, hormones and hormonal 
antagonists, antidepressants, cardiac antiarrhythmic drugs, isotretinoin, 
diphenoxylate/atropine, beta-adrenergic antagonists, chemotherapy agents, any other drug 
with anticholinergic effects 
• Other systemic conditions like sarcoidosis, lymphoma 
• Chemical injury: e.g., lime burn 
• Chronic viral infections: e.g., hepatitis C, HIV  
• Radiation to orbit or nearby area  
• Neurological conditions: Parkinson disease, Bell’s palsy, trigeminal neuralgia  
• Smoking or exposure to passive smoking  
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SIGNS: 
• Lids-may show Posterior blepharitis and meibomian gland dysfunction. 
• Conjunctiva -mild keratinisation, Non specific conjunctivitis, 
conjuctivochalasis 
• Tear film -In a normal eye, when the tear film breaks down, the mucin layer 
gets mixed with lipid but is eventually washed away. In a dry eye however, 
the lipid-contaminated mucin accumulates in the tear film as particles and 
debris that move with each blink. 
The inferior tear film meniscus height is a crude measure of the volume of 
aqueous in the tear film. In a normal eye the meniscus height is about 1 mm, while 
in dry eye it becomes thin or absent. 
Froth in the tear film or lid margin occurs in meibomian gland dysfunction. 
• Cornea -Punctate epithelial erosions that stain with fluorescein. 
Filaments consisting of mucus strands lined with epithelium attached at one end 
to the corneal surface may be present which stain well with Rose Bengal. Mucous 
plaques are composed of mucus, epithelial cells and proteinaceous and lipoidal 
material and are usually seen in association with corneal filaments. 
        
THIN TEAR FILM MENISCUS HEIGHT WITH CORNEAL STAINING 
                                              WITH FLUORESCEIN 
 
                 
 
MEIBOMIAN GLAND DYSFUNCTION 
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CLINICAL TESTS 
1)  TEAR  SECRETION ASSESSMENT: 
a)  Schirmer's test 
 It is measured with special filter paper (no.41 Whatman, 5mm wide,35mm 
long).The paper is folded 5mm from one end & inserted at junction of middle & 
outer 1/3rd  of lower lid and kept for 5 minutes with eyes open. 
Schirmer’s Test 1:  
 It measures the Total (Reflex + Basal) tear secretion. Basal secretion alone is 
measured after anesthetizing conjunctiva. Normal value is >10 mm. 
Dry Eye  
Mild   10 to 6 mm  
Moderate  5 to 3 mm 
Severe   0-2 mm  
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Schirmer’s Test 2 : 
 It is done to ascertain the reflex secretion. After the strips are installed, un-
anaesthetized nasal mucosa is irritated. It is then measured after 2 minutes. Less 
than 6mm is considered as failure of reflex secretion.  
b) Phenol red test 
 A thread impregnated with a pH-sensitive dye is used. One end of the thread 
is placed in the lower lid fornix & is left to wet. It is then measured after 15 secs. 
The dye changes from yellow to red in colour when it comes in contact with tears. 
Value of < 6mm is abnormal. This test is comparable to schirmer’s test and  takes 
less time  to perform. 
 
 
 
 
 
 
 
 SCHIRMER’S TEST 
 
 
 
PHENOL RED TEST 
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1) TEAR VOLUME ASSESSMENT 
Tear meniscus height: 
Marginal tear strip is continuous, concave meniscus between eyelid margin 
& inferior bulbar conjuctiva, where lid touches the globe  and can be easily 
visualized in Slit Lamp Examination. A tear film height of 0.5 to 1mm is 
considered normal. Scanty, discontinuous, absent tear meniscus is an important 
sign of dry eye & tear deficiency. 
TEAR MENISCOMETRY: Tear meniscus is seen noninvasively using a tear 
interference device . Tear interference image is then captured with a digital video 
camera. The quantification of the height & volume of lower lid meniscus is done. 
3) TEAR CLEARANCE ASSESSMENT 
Fluorescein clearance test (FCT) 
A normal tear turn over rate is important for removing inflammatory 
cytokines and providing fresh growth factors. Delay in tear clearance strongly 
correlates with ocular irritation symptoms independent of aqueous tear production. 
It is done by putting 5 µl of fluorescein on the ocular surface and measuring the 
residual dye with a Schirmer strip placed over the lower lateral lid margin at 
intervals of 1, 10, 20 and 30 minutes. The presence of fluorescein on each strip is 
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examined under blue light and compared to a standard scale or measured using 
fluorophotometry. In normal eyes the value will have fallen to zero after 20 
minutes 
4) TEAR FILM STABILITY 
TEAR FILM BREAK UP TIME- It is done by moistening a fluorescein 
strip with saline & applying it to lower fornix. After several blinks, tear film is 
examined using cobalt blue filter in slit lamp. The interval between last blink & 
appearance of first randomly distributed area of dark discontinuity is measured. 
TBUT<10 secs is abnormal. It is seen in both aqueous deficiency & 
meibomian gland disease.                  
NON INVASIVE TBUT: Done with the help of keratometer, keratoscope, 
tearscope. Measurement takes longer time  than fluorescein TBUT. <15 secs is 
considered dry eye. 
5) OCULAR SURFACE DAMAGE ASSESSMENT 
a) Tear film osmolarity: Values higher than 312 mOsol /litre are diagnostic 
of dry eye.It is 90% sensitive, 95% specific. A commercial osmometer specifically 
designed to test nanometer volume of tear is now in use but is not widespread due 
to cost factor. 
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       CONDITION EXPECTED RANGE OF VALUE 
Normal <312 mos/l 
Borderline dry eye 312-323 mosm/l 
Moderate/Severe dry eye >323 mosm/l 
 
b) Ocular surface dye staining 
It is done to detect ocular surface epithelial pathology associated with dry eye: 
•  Fluorescein sodium  
•  Rose bengal  
•  Lissamine green  
 FLUORESCEIN DYE TEST- most commonly done. It stains the cornea 
more than conjunctiva, in the interpalpebral area.it leads to significantly greater 
amount of staining in Sjogren’s disease and aqueous tear deficiency . 
 ROSE BENGAL STAINING: It stains tissue by penetrating into 
intercellular spaces. It stains the devitalized epithelial cells and the healthy 
epithelial cells when they are not protected by a layer of mucin. Conjunctiva stains 
more intensely than the cornea.In interpretation of rose bengal staining in dry eye 
is based on two factors(Van Bijsterveld score)-intensity and location. Its graded on 
a scale of 0 – 3 in 3 areas  
LISSAMINE GREEN-Its staining pattern is identical to Rose Bengal, but 
produces much less irritation  
 FLUORESCEIN STAINING 
                     
                                 ROSE BENGAL STAINING 
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c) Conjuctival impression cytology: 
 Its a non invasive technique.A drop of proparcaine is instilled and 
conjuctival impressions are taken  by applying cellulose acetate filter paper to 
remove superficial layers of epithelium which is then air dried & stained with PAS 
& haematoxylin /papanicalou stain and examined under electron microscope. 
Findings of cytology graded are from 0-3 
• Grade 0-Normal number of goblet cells and normal appearing epithelial cell 
with N/C ratio of 1:2 
• Grade 1-350-500 goblet cells and more polygonal epithelial cells with 
normal N/C ratio of 1:3 
•  Grade 2-100-350 goblet cells and abnormal epithelial cells with N/C ratio of 
1:4 
•  Grade 3-No goblet cells and keratinized epithelial cells with N/C ratio of 
1:6  
Grade higher than 1 are abnormal. 
 
 
 
 
  
CONJUCTIVAL IMPRESSION CYTOLOGY 
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d) Conjunctival and corneal sensation :  
 Decreased corneal sensation can be both the cause and the effect of dry eye. 
Sensory denervation may lead to dry eye by reducing the afferent signal, reducing 
the blink rate, altering growth and differentiation of ocular surface through trophic 
influence of trigeminal nerve, Auto immune sensory neuropathy and sensory 
neural degeneration due to inflammation or chronic over stimulation. CORNEAL 
ESTHETIOMETRY can be done for the same. 
e) Tear protein analysis  
In small unstimulated tears protein levels are 2gm% and in stimulated tear- 
0.3-0.7gm%. Various proteins that are found in normal tear are IgG, Albumin, 
transferrin, alpha 1 antitrypsin, beta 2 microglobulins , lysoyme, lactoferrin, IgA.  
f) Crystallization /Ferning test:  
Tear film composition affects the way in which a collected sample of tear 
dries on a glass slide. This test is based on mucus ferning patterns. Tears are 
collected in a glass capillary & placed on a glass slide & left to dry at room 
temperature. The sample is then observed in white light or by polarized 
microscopy & classified in to various grades depending on crystallization. The 
tears of dry eye patient exibit less ferning than those of normal patients. Test may 
reflect the quality of tear protein profile.  
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TREATMENT 
The aims for treating dry eye disease include:  
• To diagnose the dry eye condition and recognise its various causes. 
• To educate and involve the patient in the management of these chronic 
disease states. 
• To establish an appropriate therapeutic regimen. 
• To prevent long term complications such as infections or permanent 
structural damage 
This can be achieved by– 
1) Tear supplementation 
2) Tear conservation 
3) Tear stimulation 
I) TEAR SUPPLEMENTATION 
1) Artificial Tear substitutes:  
An ideal artificial tear would have the same metabolic, optical and physical 
characteristics as that of natural tears.5Additionally, it would have a long ocular 
residence time and would contain therapeutic additives to treat primary and 
secondary damage to the eye.5 
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3)Lacrimal occlusive devices: 
a) Temporary:   
Inserting collagen plug into canaliculi which dissolve over weeks. Main aim is 
to ensure epiphora does not occur following permanent occlusion. At first, inferior 
puncta alone is occluded and patient is asked to review after 1 to 2 weeks. If 
patient is asymptomatic, without any epiphora, plug is removed & inferior 
canaliculi is permanently occluded. In cases with severe KCS, both inferior and 
superior canaliculi needs to be plugged. 
b) Reversible:  
Prolonged occlusion with silicone or long lasting (2-6 months)plug. Its 
disadvantage being extrusion, granuloma formation,distal migration,infection.  
c) Permanent occlusion:  
 Its done in patients with Severe dry eye(who had positive response with 
temporary occlusion without epiphora). It is avoided in young patients who have 
reversible pathology. All 4 puncta are occluded at same time. Done following 
punctal dilatation by coagulating the puncta with cautery. Laser cautery less 
effective than surgical thermal coagulation. 
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MECHANISM OF ACTION 
1) Provides viscous layer which stabilizes and thickens pre corneal tear 
film. 
2) Prolongs tear film break up time. 
3)  Keeps ocular surface wet and lubricated. 
4)  Helps to repair ocular surface damage. 
5) Keeps ocular surface smooth. 
Polymer based- most commonly used. These are water based formulations 
with polymers added to enhance viscosity, lubrication, retention time, and stability. 
1) Polysaccharides and vinyl derivatives:  
Polysaccharides like mucilages, dextrans, and viscoelastic substances and 
vinyl derivatives are the most common polymers used. 
a) Substituted cellulose esters: Methyl cellulose for mild cases. 
 Hydroxy methyl cellulose, Hydroxy propyl methyl cellulose, Carboxy 
propyl methyl cellulose. These are longer lasting and adhere to ocular surface 
a) Viscoelastic agents: Sodium hyaluronate, Sodium chondroitin sulphate 
b) Vinyl derivatives: Polyvinyl alcohol, Polyvinyl Pyrrolidone.  
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Other ingredients:  
2) Electrolytes:  
 It helps to maintain or lower the osmolarity of artificial tears as compared to 
natural tears. Some are important for corneal epithelial metabolism like sodium 
chloride and potassium. Hypotonic tear formulations tend to reduce tear osmolarity 
and cause relief. HYPOTEARS, THERA TEARS are such formulations. 
3)Buffers:  
 Artificial tears with a pH approaching 8.5 are more comfortable for dry eye 
patients. Some common buffer systems are phosphate, phosphate-acetate, 
phosphate-citrate etc 
4)Nutrients :  
 Dextrose, sodium lactate, sodium citrate, vitamins A, B12, C. 
5)Preservatives:  
They inhibit the growth of microorganisms, by bacteriostatic effect and 
increases the shelf life of medication. Also helps in increasing corneal penetration 
of medications. 
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  Various preservatives that are available: Benzalkalanium chloride (most 
toxic), cholorobutanols, thiomersals, EDTA, sodium perborate. 
Complications of tear substitutes with preservatives include pigmentation, 
irritation, papillary and follicular conjunctivitis, superficial punctate keratitis, 
epithelial cell exfoliation. 
2)Gels:  
It is a semi solid formulation tat persists in cul-de-sac for a longer period of 
time. This decreases the frequency of application and is more effective in relieving 
the symptoms and signs. 
3)Mucolytic agents: 
 
 It softens the mucus and make it more fluid. Its available as 5% or 10% 
acetylcysteine. It has an intracellular effect on goblet cell during mucin formation, 
facilitating production & improving quality. It is useful in treating patients with 
corneal filaments and mucous plaques. 
4) Serum eye drops: 
 
 It is a prepared from autologous or umblical cord serum(20-100%). It is 
found to be very useful in sjogren’s syndrome patients. 
5) Artificial tear inserts : 
  Lacrisert (merck) is a sterile, translucent, water soluble cylindrical rod which 
is 1.25mm wide and 3.50mm long containing 5mg preservative free hydroxypropyl 
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cellulose which is placed into inferior fornix. It imbibes water, swells and 
dissolves. Effect begins after 1 h & remains for 14–24 h, so 1 insert / morning is 
enough for 1 day. It stabilizes & thickens precorneal tear film. 
II) TEAR CONSERVATION 
Includes the techniques used to reduce evaporation. 
1) Environmental modifications:  
By bringing life style changes like humidifiying ambient air by using 
humidifiers, lowering computer screen below eye level, regular reading breaks, 
with eyes closed during rest, increasing blink frequency, by avoiding- wind, air 
conditioning, dry heat, high altitudes, smog, exhaust, tobacco smoke, prolonged 
computer/ television use, prolonged contact lens wear. 
2) Ointments:  
 Petrolatum, mineral oil, lanolin are the esters of fatty acids with long chain 
alcohol which serve as lubricants and create a lipid layer retarding evaporation. It 
is used as a bed time dosage to supplement day time drops and avoided in day time 
as it can cause blurring of vision. 
 
 
PUNCTAL PLUG 
 
                                                         
PUNCTAL PLUG IN PLACE 
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III) TEAR STIMULATION 
Secretagouges 
 -Diquafosol 3%  is a newer agent that acts as a topical secretagogue. P2Y2 
purinogenic agonists stimulate secretion of tear fluid and mucin on ocular surface 
and increase tear film stability. 
       -Oral cholinergic agonists like pilocarpine(5mg 4 times daily) & 
cevilemine(30 mg 3 times daily) bind to the muscarinic receptors and stimulate 
secretion of tears 
       -Bromhexine 
       -Rebamipide- newer drug, a mucin secretagouge 
IV. Other Management 
 Systemic medications: Systemic omega-3 fatty acids like fish oil,flax seed 
oil .It inhibits the synthesis of pro-inflammatory mediators. 
Surgeries: Repair of eyelid -Trichiasis, Entropion, Ectropion ,Lateral 
Tarsorrhaphy, Amniotic membrane transplantation, Submandibular gland 
transplantation. For cases with very severe dry eye, Keratopreosthesis is the only 
option to restore vision. 
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Anti-inflammatory agents: 
• Topical steroids:  Low potency steroids like fluoromethalone, lotepred 
0.5% in frequent intervals for 2 weeks is an effective supplementary 
treatment for acute excerbation. It reduces the ocular inflammation. 
• Topical ciclosporin (0.05%)  When applied twice daily, it can reduce T-
cell mediated inflammation of lacrimal tissue and  increase the number of 
goblet cells. 
• Oral tetracyclines: Given as extended course for 3 months at low dose. It 
helps in controling blepharitis, meibominitis and reduces the tear levels of 
inflammatory mediators. 
Moisture Chamber Spectacles 
Contact lenses:  Though contact lens wear exacerbate inflammatory & evaporative 
effects ,benefits outweigh the side effects. It acts by the fluid trapped behind the lens 
,thereby effective by relieving symptoms. HEMA lenses for moderately dry eye, Silicone 
rubber lenses and Occlusive gas permeable scleral contact lens for extreme dry eye. 
Botulinum toxin injection- 
To orbicularis muscle at medial canthus, is given to control blepharospasm in 
severe dry eye. Also reduces tear drainage by limiting the lid movement. 
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STRATEGY FOR TREATMENT 
DEWS guidelines based on earlier international taskforce  
Level 1: Mild to moderate symptoms, no signs                
               Mild to moderate conjuctival signs 
Stategy    
 1) Education & environmental/dietary modifications:  importance of 
compliance 
  Lifestyle review (importance of blinking, using computer screen below eye 
level) 
  Aids for instillation of eye drops 
  Caution the patient that laser refractive surgery would not be possible 
  Systemic medication review 
  Artificial tear substitutes(use of preserved drops come under level 1,non-
preserved drops categorized under level 2) 
  Eyelid therapy: hygiene, lid surgery, tapping of eyelids, swimming goggles, 
tarsorraphy 
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 Level 2      
Moderate to severe symptoms tear film signs, visual signs 
Mild corneal punctate staining 
Mild conjuctival staining 
Strategy: 
Non-preserved tear substitutes 
Anti-inflammatory agents(topical steroids,omega fatty acids,topical 
ciclosporin) 
Tetracyclines  
Punctal plugs 
Secretagogues (pilocarpine,cevilemine,rebamipide)  
Moisture chamber spectacles 
Spectacle side shields 
Level 3        
 Moderate to severe symptoms 
Marked corneal punctate staining 
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     Central corneal staining 
     Filamentary keratitis 
Strategy: 
Serum eye drops 
Contact lenses 
Permanent punctal occlusion 
Level 4       
 Severe symptoms 
 Severe corneal staining and erosions 
 Conjuctival scarring 
Strategy: 
Systemic anti-inflammatory agents 
Surgery-eyelid surgery, tarsorraphy, salivary gland autotransplantation, 
mucous membrane/amniotic membrane transplantation. 
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DRY EYE CONSENSUS GUIDELINES (DELPHI MODEL) 2006-07 
Proposed a new terminology for dry eye- DYSFUNCTIONAL TEAR 
SYNDROME (DTS). It classified the DTS into 3 major categories and subset of 
each of these categories are distinctly different from each other in terms of their 
pathology and the treatment recommendations. The classification was based on the 
site of lid pathology, anatomical and functional abnormalities. 
Classification: 
1) With lid margin disease- anterior and posterior 
2) Tear distribution problems-conjuctivochalasis, lid ans lash abnormalities, 
elevated surface lesions, reduced blink rate 
3) Without lid margin disease 
DTS was classified into 4 levels based on severity of the signs and symptoms. 
The diagnostic tests were considered secondary. 
This study recognised that most of the cases of DTS had an underlying 
inflammation as causative agent. It also confirmed that patients may move in 
between the various severity levels, and if left untreated may lead to complications. 
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PROGRESSION OF DRY EYE SEVERITY LEVELS 
LEVEL 1 Mild to moderate symptoms ,no signs  
Mild to moderate conjunctival signs 
LEVEL 2 Moderate to severe symptoms 
Tear film signs,visual signs 
Mild corneal punctuate staining 
Conjunctival staining 
LEVEL 3 Severe symptoms 
Marked corneal punctuate staining 
Central corneal staining 
Filamentary keratitis 
LEVEL 4 Severe symptoms 
Severe corneal staining,erosions 
Conjunctaval scarring 
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                                       DRY EYE TREATMENT CHART 
SEVERITY 1 2 3 4 
Symptoms Mild To Moderate Moderate To Severe Severe Severe 
Conjunctiva
l Signs 
Mild To Moderate Staining Staining Scarring 
Corneal 
Staining 
 Mild Punctate Staining Marked Punctate 
Staining, Central 
Staining, 
Filamentary 
Keratitis 
Severe 
Staining 
Other Signs  Tear Film:Vision 
Blurring 
  
                                                 TREATMENT OPTIONS 
 -Patient 
Education 
-Environmental 
Modification 
-Preserved Tears 
-Control Allergy 
-Unpreserved Tears 
-Gels ,Ointments 
-Topical Prescription 
Therapies 
- Secretagogues 
-Nutritional Support 
-Oral 
Tetracycline 
- Punctal Plugs 
-Systemic Anti-
inflammatory 
Therapy 
-Oral 
Cyclosporin 
-Acetylcysteine 
-Moisture 
Goggles 
-
Surgery(Punctal 
Cautery) 
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DEWS( Dry Eye Work Shop) Guidelines 
DEWS based the revised classification scheme on the updated Triple 
Classification published in 2005 and the report of the Delphi Panel published in 
2006. A three-part classification system was developed.  
The first part is etiopathogenic and illustrates the multiple causes of dry eye.  
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The second is mechanistic and shows how each cause of dry eye may act 
through a common pathway, and that any form of dry eye can interact with and 
exacerbate other forms of dry eye as part of a vicious circle.  
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The third is a scheme based on the severity of dry eye disease, which is 
expected to provide a rational basis for therapy 
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OSDI QUESTIONNAIRE 
It is widely used by ophthalmologists these days to diagnose dry eye disease. 
This questionnaire being easier to understand to given to the patient themselves to 
monitor the progress of the disease 
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                               ANTI-PSYCHOTIC AGENTS 
CLASSIFICATION: 
1) PHENOTHIAZINES: 
Aliphatic side chain -  Chlorpromazine, Triflupromazine 
Piperidine side chain - Trifluoperazine 
Piperazine side chain - Trifluoperazine, Fluphenazine 
2)  BUTYROPHENONES Haloperidol, trifluperidol, Droperidol,  
Penfluridol 
3) THIOXANTHINES - Thiothixene, Flupenthixol 
4) OTHER HETERO 
CYCLICS -  Pimozide, Loxapine 
5) ATYPICAL  
NEUROLEPTICS -  Clozapine, Olanzapine, Risperidone 
 
 
 
 
40 
 
PHARMACOLOGICAL ACTIONS: 
1) CNS-  In normal individuals, it causes paucity of thought, indifference to 
surroundings,  psychomotor slowing, tendency to sleep off from which he is easily 
arousabe. Spontaneous movements are minimised. This is known as 
NEUROLEPTIC SYNDROME. 
In psychotic individuals, it reduces irrational behaviour, agitation and 
aggressiveness. Hyperactivity, hallucinations and delusions suppressed. 
Aliphatic and piperidine side chains have low potency but more sedative 
action. Extrapyramidal side effects and anti-emetic effects are related to anti-
psychotic effects least with Thioridazine. 
Mechanism of action- D2( Dopamine receptors) blocking effect in the limbic 
system and mesocortical area is responsible for anti-psychotic effect except 
clozapine. Clozapine has 5HT2 and alpha1 blocking action and D4 blocking effect 
as well. Dopaminergic blockade in basalganglia is responsible for extra-pyramidal 
effects and in CTZ for anti-emetic action. 
c) ANS:  
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Alpha 1 blocking effect-
CPZ=triflupromaizne>thioridazine>fluphenazine>haloperidol>trifluoperazine>
clonazapine>pimozide 
Anticholinergic effect-thioridazine>chlorpromazine> 
triflupromazine>trifluperazine=haloperidol. 
H1, 5HT blocking effect-phenothiazines. 
3) LOCAL ANAESTHETIC- Chlorpromazine has potent local anaesthetic 
effect. 
4) CVS-Hypotension due to central and peripheral effect on sympathetic tone. 
High doses of CPZ depresses heart. However,it has some membrane stabilizing 
effect. 
5) SKELETAL MUSCLE- reduces some types of spasticity due to action in 
basal ganglia and medulla. 
6) ENDOCRINE- increases prolactin levels by blocking dopamine receptors in 
pituitary lactotrophes. Reduces onadotrophin secretion, ACTH, GH, ADH release. 
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                                  ADVERSE EFFECTS 
BASED ON PHARMACOLOGICAL ACTIONS( DOSE RELATED) 
1) CNS- Lethargy, drowsiness, confusion and weight gain, aggravation of 
seizures in epileptic patients. 
2) ADRENERGIC BLOCKING  EFFECTS-postural hypotension, 
palpitation, inhibition of ejaculataion. 
3) ANTI-CHOLINERGIC EFFECTS-dry mouth, constipation, urinary 
hesitancy in elderly males, blurring of vision. Clonazepine may induce 
hypersalivation due to centra action. 
4) ENDOCRINE-amenorrhoea, infertility, gynaecomastia, galactorrhoea 
5) EXTRAPYRAMIDAL SIDE EFFECTS-Parkinsonism, Tardive 
dyskinesia, Acute muscular dystonias, akathisia, Malignant neuroleptic syndrome,. 
6)MISCELLANEOUS- weight gain, bluish pigmentation of exposed skin, 
corneal and lenticular degenrations, retinal degeneration (more with thioridazine). 
Cardiac arrhythmias, myocarditis. 
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HYPERSENSITIVITY REACTIONS 
1) Cholestatic jaundice 
2) Skin rashes, urticaria, contact dermatitis, photosensitivity & 
Agranulocytosis 
USES 
1) PSYCHOSES 
Schizophrenia- used primarily in functional psychoses. They control positive 
symptoms of schizophrenia better than negative symptoms. They tend to restore 
cognitive, affective and motor disturbances. 
•  In agitative, combative and violent patients-CPZ, triflupromazine, 
haloperidol. 
• Withdrawn and apathetic-trifluperazine, fluphenazine 
• Negative symptoms and resistant cases-clozapine, olanzapine 
• Mood elevation, hypomania-haloperidol, fluphenazine. 
• In chronic schizophrenia, effect may be seen after 2-4 months of therapy. 
• Mania – in acute episode, i.m. injections of lithium and carbamazapine can 
be given, whichcan be tapered later. 
•  Organic brain syndromes 
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2) ANXIETY- the patients not responding to anxiolytics or have a psychotic 
basis for anxiety may be treated with this class of drugs. 
3) ANTI-EMETIC- for drug and disease induced vomiting at low doses. But 
ineffective in motion sickness. 
4) OTHER USES :  
• To potentiate hypnotics, analgesics, anaethsetics 
• Intractable hiccough- responds to parentral CPZ 
• Tetanus-CPZ is used for muscle relaxation. 
• Alcohol hallucinosis, huntington’s disease, gilles de la tourette’s syndrome. 
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OCULAR SIDE EFFECTS OF ANTI-PSYCHOTICS 
Psychoactive drugs are prescribed frequently for a variety of conditions to alter 
mood and emotional status. Whether it’s short-term use of an antidepressant or a 
lifelong reliance on an anti-schizophrenia drug, most of the people will meet the 
criteria for a DSM-IV and -V disorder at some point in their lifetime. Because of 
chronicity of neuroleptic usage, they show a lot of side effects Liver is the most 
common drug to show drug toxicity, followed by eye. 
1) Ocular Surface 
Drug toxicity to the ocular surface can manifest in the form of corneal 
edema, epithelial keratopathy, and altered tear film.11  
Phenothiazines can cause phototoxic lysis of the corneal endothelium which 
in turn is linked to the total dosage of medication. This can lead to impaired 
endothelial pump function, causing severe corneal edema and consequent visual 
effects.12 
Chlorpromazine has been found to cause corneal epithelial keratopathy.11It 
has a distinctive pattern of fine streaks or swirling lines in the epithelium. This has 
been linked to high dosages (>2g/day) of the drug.11 This causes minimal visual 
consequences and usually regresses with dose tapering. An innocuous, subtle, 
diffuse yellowish-brown granular deposits in the endothelium, Descemet 
  
 
 
 
GRANULAR ENDOTHELIAL DEPOSITS 
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membrane and deep stroma occurring only in exposed cornea of the interpalpebral 
fissure is also common. 
Psychiatric medications can also alter the quantity and quality of tears. 
These medications due to their anticholinergic effects tend to alter the tear film.  
Clozapine, an atypical antipsychotic medication, exhibits anticholinergic side 
effects by blocking muscarinic and nicotinic receptors, and muscarinic-3 receptors 
in the conjunctiva and lacrimal gland as well.10This leads to decreased mucous and 
aqueous secretion.10 Persistent tear film instability can lead to morphological and 
biomechanical changes at the cellular level, ultimately affecting the ocular surface 
and vision.11 Prompt lubrication and use of tear rehabilitating agents as 
cyclosporine can prevent desiccation. 
2) Ocular Pigmentation 
Chlorpromazine is more likely to cause pigmentary changes compared to 
clozapine.4,13,14 Ocular pigmentation following drug toxicity can be divided into 
two groups: pigmentation of the skin, conjunctiva, cornea or lens and pigmentary 
retinopathy.13,14 The first may cause minimal to no changes in vision, while 
pigmentary retinopathy may lead to irreversible degenerative retinopathy.   
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Chlorpromazine is found to accumulate in the skin of the lids, conjunctiva, 
posterior corneal stroma, lens and uvea.4,13,14 As it is phototoxic, it is postulated 
that photosensitization of the tissue proteins occurs in areas of sun exposure after 
accumulation of the drug in these tissues.13,14 Protective dark goggles and reduced 
exposure to sun ,while on the medication is recommended for these 
patients. Although these pigmentary changes are not that common with clozapine, 
there have been reports with a handful of cases. 
3) Uveal tissue 
Antipsychotics with a strong anticholinergic and/or antiadrenergic effects 
(like chlorpromazine and fluphenazine) can cause mydriasis and cycloplegia. Due 
to this, there is a weakened accommodation leading to blurring of vision. 
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4) Lenticular Opacities and Cataracts 
Cataracts secondary to these medications are rarely bilateral and usually 
asymmetric.15This may be due to unequal deposition of medication in the lens. 
Additionally, atypical antipsychotics can cause metabolic syndrome, 
hyperglycemic status in these patients can cause an early diabetic cataract 
formation.15  
Phenothiazines are the most common antipsychotic agents that can lead to 
formation of lenticular opacities.4,7,8 There is a deposition of fine, stellate, 
yellowish-brown granules on the anterior lens capsule in the pupillary area in 50% 
of patients who have received a cumulative dose of 1000 g. The deposits persist 
despite discontinuation of the drug. The normal daily dose is 75–300 mg. The 
corneal pigmentation occurs in conjuction to anterior subcapsular pigment, which 
shows a link to alterations in the aqueous humor.15,16 Phototoxicity is thought to be 
a potential mechanism of action, although an alternate explanation can be lens 
discoloration. In certain cases, endogenous melanin in the eye may trap free 
radicals produced by psychotropic medications, which shows up as lens 
discoloration.15,16 These opacities may not reverse with cessation of the 
medication, however any visual disturbance due to it will vary depending on the 
duration of exposure and degree of damage. 
 
ANTERIOR SUB-CAPSULAR DEPOSIT 
 
 
 
ASYMMERTRICAL LENTICULAR OPACITIES 
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5) IOP and Angle Closure Glaucoma 
Typical antipsychotics having anticholinergic effects can cause an acute angle 
closure with pupillary block in patients with anatomically narrow angles.8 The 
mechanism is believed to be drug-induced mydriasis in an already crowded angle. 
Thus, these drugs should be prescribed cautiously in patients with already narrow 
angles. 
6) Retinopathy 
Ocular pigmentation caused by phenothiazines as thioridazine and 
chlorpromazine, can occur in the retina. The risk with thioridazine is based on 
large daily doses of >800 mg/day (Normal daily dose is 150–600 mg) , while the 
risk with chlorpromazine is related to daily dosage and duration of 
use.4,8,24 Pigment gets deposited from the peripheral to central retina giving rise to 
a Salt and Pepper pigmentary disturbance.24 A plaque-like pigmentation and focal 
loss of the RPE and choriocapillaris which is later followed by diffuse loss of the 
RPE and choriocapillaris as the disease progresses. It has been postulated that 
phototoxic stress causes peripheral vision loss, nyctalopia, permanent vision loss 
and ultimately blindness as damage progresses.23 Early detection and intervention 
can prevent permanent visual damages.  
                   
                             
 
 
 
PIGMENTARY RETINOPATHY 
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7) Ocular Motility Disorders 
Oculogyric crisis caused by dystonia, occurs due to involuntary contractions 
of extraocular muscles. This can cause gaze paralysis which may be painful and 
even life-threatening if systemic muscles get involved.5 The etiology is believed to 
be dopamine receptor blockage along with other causes.6,8 Treatment consists of 
anticholinergic agents ( intramuscular benzatropine) and antihistamines 
(diphenhydramine) and can rapidly reverse the symptoms.4,6,8  
8) Impaired Sensory Perception 
Changes to color vision and contrast sensitivity has been noted with psychiatric 
medications. Regular color vision and contrast sensitivity testing should be done in 
these patients. 
9) Metabolic and Cerebrovascular Implications 
Although its proved that newer antipsychotics have safer toxicology profiles 
as compared to typical antipsychotics, newer medications can still cause metabolic 
syndrome. Impaired glucose metabolism, exacerbation of existing diabetes, 
induction of Type 2 diabetes and diabetic ketoacidosis have been linked to 
antipsychotic medications.15,33  
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Therefore, we should routinely screen for diabetic retinopathy in patients on 
chlorpromazine, clozapine and olanzapine.15,33 
Lastly, there has been found to be a increased risk of cerebrovascular events 
in elderly patients with dementia who are on antipsychotic medications.33 Typical 
antipsychotic agents have been associated with a higher risk of cerebrovascular 
accidents than that with atypical agents. 
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AIM 
The aim of the study is to find out any disturbance in tear film due to chronic 
usage of Anti-psychotic medications in patients attending the Psychiatry OPD, 
Govt Stanley Medical College and Hospital . 
1) To determine the prevalence of dry eye disease in patients on chronic 
anti-psychotic therapy.  
2) To determine the association between duration of therapy and dry eye 
disease. 
3) To determine the association of poly-pharmacy with dry eye disease in 
these patients. 
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MATERIALS AND METHODS 
It is a cross sectional observational study undertaken on 200 eyes of 100 
patients who were on chronic anti-psychotic therapy attending the Psychiatry OPD. 
Out of 100 patients, 65 patients were male, rest 35 were females. 76 patients were 
on treatment for schizophrenia, 15 had Delusional disorder and 9 had Psychoses-
not specified otherwise. 
Study period was from 2015-2016 
INCLUSION CRITERIA: 
• Patients on Anti-psychotic medications for more than 2 years. 
EXCLUSION CRITERIA: 
• Patients on Anti-psychotic medications for less than 2 years. 
• Patients who had an acute episode of the disease. 
• Patients on other medications along with Anti-psychotics. 
• Patients with other ocular morbidities which can affect tear film. 
• Other systemic diseases. 
The importance of ocular examination was thoroughly explained to the 
patients and their caretaker in their own language. 
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Consent from the patients and their caretakers was obtained in their own 
language from all those who were willing to take part in the study.  
Any photographic records of the lesions were taken only if the patient 
consented for the same. 
Literature of approval attached. 
History regarding Anti-psychotic drug usage, its dosage and duration was 
obtained from the patients and care-takers. 
OCULAR EXAMINATION WAS DONE AS FOLLOWS: 
• Ocular history 
• Ocular examination included: 
• Best corrected visual acuity by Snellens Chart 
• Slit lamp examination & dilated fundus examination -90D and 20D 
DRY EYE EVALUATION: 
• Schrimer’s 1 test: 
• Tear film height: 
• Tear film break up time: 
• Fluorescein staining : 
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RESULTS AND DISCUSSION 
32 out of 100 patients on chronic anti-psychotic therapy had dry eye disease.  
17 (53.13%) out of these 32 patients had symptoms suggestive of dry eye 
disease.  
 
 
 
 
 
 
 
 
ABSENT 
68% 
PRESENT 
32% 
Dry Eye Prevalence 
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1) AGE DISTRIBUTION: 
AGE 
GROUPS 
NUMBER OF PATIENTS 
WITH DRY EYE DISEASE 
NUMBER OF EYES WITH 
DRY EYE DISEASE 
< 20 2 4 (6.7%) 
21-40 10 19 (32.2%) 
41-60 19 36 (61.01%) 
TOTAL 32 59 
 
Most of the patients with dry eye disease belonged to the age group of 41-60 
years constituting 61% of total eyes with dry eye disease. 
AGE-WISE DISTRIBUTION OF DRY EYE DISEASE       
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57 
 
2) GRADING OF DRY EYE DISEASE: 
59 out of 200 eyes had dry eye disease. 3 patients out of 32 had unilateral 
dry eye disease. 
DEWS SEVERITY GRADING NUMBER OF EYES 
1 1 (1.6%) 
2 27 (45.76%) 
3 23 (38.98%) 
4 8 (13.55%) 
TOTAL 59 
 
27(45.7%) eyes out of 59 eyes diagnosed with dry eye had Grade 2 dry eye 
disease. 
 
GRADE 1 
2% 
GRADE 2 
46% GRADE 3 
39% 
GRADE 4 
13% 
DEWS GRADING OF DRY EYE 
DISEASE 
GRADE 1 
GRADE 2 
GRADE 3 
GRADE 4 
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2) SYMPTOMS 
 
                       SYMPTOMS 
NUMBER  OF PATIENTS 
WITH DRY EYE 
Irritation/ Foreign Body Sensation 10 (31.25%) 
Burning Sensation 2 (6.25%) 
Discomfort To Bright Light/ Wind 5 (15.62%) 
No Symptoms 15 (46.87%) 
TOTAL 32 
 
 17 (53.13%) out of 32 patients with dry eye disease had symptoms. 
Considering this, we should pay importance to their symptoms and evaluate them 
further objectively.  
15 out of 32 did not have any complaints. As most of the patients were in 
Grade 3 dry eye disease category, we should definitely evaluate these patients even 
if they are asymptomatic. 
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3) TEAR FILM MENISCUS HEIGHT 
TEAR FILM MENISCUS HEIGHT NUMBER  OF  EYES WITH DRY 
EYE 
Abnormal 55 (93.2%) 
Normal 4 (6.8%) 
Total 59 
 
Tear film height was abnormal in 55(93.2%) out of 59 eyes with dry eye 
disease. 
 
 
32.25% 
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16.12% 
48.38% 
SYMPTOM WISE DISTRIBUTION 
IRRITATION/ FOREIGN BODY 
SENSATION 
BURNING SENSATION 
DISCOMFORT TO BRIGHT 
LIGHT/ WIND 
NO SYMPTOMS 
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4) CONJUNCTIVAL INJECTION 
 
 
 
 
 
Conjunctival injection was absent in 47 out of 59 eyes that constitutes nearly 
79.66% of positive cases. 
5) CONJUNCTIVAL STAINING 
CONJUNCTIVAL STAINING NUMBER  OF  EYES WITH 
DRY EYE 
Absent 11 (18.64%) 
Mild 36 (61.01%) 
Moderate 10 (16.94%) 
Severe 2 (0.33%) 
Total 59 
 
Conjunctival staining with fluorescein was positive in 48 (81.64%) eyes out 
of 59 diagnosed with dry eye disease.  
CONJUNCTIVAL INJECTION NUMBER  OF EYES WITH DRY 
EYE 
Absent 47 (79.66%) 
Present 12 (20.33%) 
Total             59 
61 
 
 
 
6) CORNEAL STAINING 
 
CORNEAL STAINING NUMBER  OF EYES WITH DRY 
EYE 
Absent 16 (27.11%) 
Mild Staining 32 (54.3%) 
Marked Central Staining 6 (1.01%) 
Diffuse Punctate Staining 5 (0.84%) 
Total 59 
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Nearly 43( 72.89%) out of 59 eyes with dry eye showed corneal staining 
with fluorescein. Most of the patients had mild corneal staining. 
 
6) TEAR FILM BREAK UP TIME  
TBUT NUMBER  OF EYES WITH DRY 
EYE 
Abnormal 38 (64.4%) 
Normal 21 (35.6%) 
 
38 (64.4%) out of 59 eyes with dry eye disease had abnormal tear film break up 
time. 
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7) SCHIRMER’S  TEST 1 
 
SCHIRMER’S              
TEST 1( in mm Hg) 
GRADE OF DRY 
EYE DISEASE 
NUMBER  OF EYES 
WITH DRY EYE 
6-10 Mild 28  (47.45%) 
3-5 Moderate 21  (35.59%) 
0-2 Severe 10  (16.94%) 
Total 59 
 
Most of the patients had mild dry eye disease, 28 (47.45%) out of 59 eyes. 
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8) DRUG WISE DISTRIBUTION OF DISEASE: 
The most commonly used Anti-Psychotic drugs in our setup is 
Chlorpromazine, Haloperidol and Risperidone.  
Chlorpromazine and Haloperidol are the Typical Anti-Psychotic agents, 
while Risperidone falls in a relatively newer category of Atypical Anti-psychotic 
agents. 
Of the 100 patients evaluated, 20 were on Chlorpromazine, 23 on 
Haloperidol and 16 on Risperidone. 
Out of  20 patients who were on Chlorpromazine , 3 (15%) had dry eye 
disease. 
Of the 16 patients on Risperidone , 2 (12.5%)patients had dry eye disease. 
And Out of 23 patients who were on Haloperidol, 3(13.04%) patients had dry eye 
disease. 
DRUG DRY EYE DISEASE TOTAL NO OF EYES PRESENT ABSENT 
Haloperidol 6 (13.05%) 40(86.95%) 46 
Risperidone 4(12.5%) 28(87.5%) 32 
Chlorpromazine 3(15%) 17(85%) 20 
Total 13 85 98 
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On comparison, the prevalence of dry eye disease showed following order: 
Chlorpromazine > Haloperidol> Risperidone. 
43 patients out of 100 were on Typical anti-psychotics. Of these, 6 (13.95%) 
patients had dry eye disease. Of the 16 patients on Atypical anti-psychotics, 2 
(12.5%) had dry eye indicating more prevalence of dry eye disease in patients on 
Typical Anti-psychotics than on Atypical agents. 
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9) DURATION OF DRUG THERAPY 
DURATION DRY EYE DISEASE TOTAL PRESENT ABSENT 
<5 Years 3 (9.4%) 16 (23.5%) 19 
5-8 Years 4 (12.5%) 30 (44.1%) 34  
>8 Years 25 78.1%) 22 (32.4%) 47  
Total 32 68 100 
 
Nearly 78% of the patients found to have dry eye disease were on treatment 
with anti-psychotic agents for more than 8 years. 
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Value df
Asymp. Sig. (2-
sided)
Pearson Chi-
Square
18.392a 2 .000
Likelihood Ratio
19.205 2 .000
Linear-by-Linear 
Association
13.302 1 .000
N of Valid Cases
100
Chi-Square Tests
a. 0 cells (0.0%) have expected count less than 5. The minimum 
expected count is 6.08.
 
p value is <0.01, proving that the association between the duration of 
treatment and  dry eye disease is significant. 
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10) MONO-PHARMACY VS POLY-PHARMACY: 
Of the 100 patients, 60 were on mono drug therapy. Rest 40 were on multi-
drug therapy. 
In the Multi-drug group, a combination of Haloperidol, Chlorpromazine and 
Risperidone was used by 4 patients, 26 patients were on Haloperidol and 
Chlorpromazine and 10 patients were on Risperidone and Chlorpromazine 
combination. 
TREATMENT             DRY EYE DISEASE TOTAL 
ABSENT PRESENT 
Mono Drug 
Therapy 
51 (75%) 9(28.1%) 60 
Dual Drug 
Therapy 
16 (23.5%) 20 (62.5%) 36 
Multi Drug 
Therapy 
1 (1.5%) 3 (9.4%) 4 
Total 68 32 100 
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Value df
Asymp. Sig. (2-
sided)
Pearson Chi-Square 20.547
a 2 .0005
Likelihood Ratio 20.689 2 .000
Linear-by-Linear 
Association
19.805 1 .000
N of Valid Cases 100
a. 2 cells (33.3%) have expected count less than 5. The 
minimum expected count is 1.28.
Chi-Square Tests
 
p value  = <0.01, proving the association between poly-pharmacy and dry 
eye disease is significant. 
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DRUG REGIMEN 
DRY EYE DISEASE TOTAL  
NO OF 
EYES 
PRESENT ABSENT 
Halo+Risp+Cpz 6 (75%) 2 (25%) 8 
Halo+Cpz 30 (57.69%) 22(43.31%) 52 
Risp+Cpz 4 (40%) 16 (60%) 20 
Halo 6 (13.05%) 40(86.95%) 46 
Risp 4(12.5%) 28(87.5%) 32 
Cpz 3(15%) 17(85%) 20 
Total 59 141 200 
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DRUG COMBINATION AND DRY EYE DISEASE 
 
        Patients with dry eye disease were given treatment according to the DEWS 
guidelines. 
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SUMMARY 
1) 32 patients out of 100 patients on anti-psychotic medications for more than 2 
years had dry eye disease. Of the 200 eyes evaluated, 59 eyes were found to have 
dry eye disease. 
2) 61.01% of the eyes with dry eye disease were between 41-60 years of age 
and on treatment. 
3) 45.7% of patients had Grade 2 dry eye disease according to DEWS 
guidelines. 
4) Nearly 53.13% patients with dry eye disease were symptomatic. Most 
common symptom being Foreign body sensation present in 32% cases. 
5) Tear film meniscus height was reduced in 93.2% of cases. 
6) The Schirmer’s test 1, fluorescein staining, tear film break up time were 
highly diagnostic of dry eye disease. 
7) No dry eye associated complications were present in any patients 
8) Of the Anti-Psychotic medications used in our study, Dry eye disease was 
found to be more common with Chlorpromazine(15%) > Haloperidol (13%)> 
Risperidone(13.5%). 
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9) Typical antipsychotics (13.95%) showed more prevalence of dry eye disease 
than Atypical antipsychotics(12.5%). 
10) Patients on Multidrug regimen showed more prevalence of dry eye that is 
nearly 75% than dual (58%) or mono drug regimen(40%). Combination of triple 
drugs, Haloperidol, Chlorpromazine and Risperidone had more cases of dry eye 
followed by patients on Haloperidol and Chlorpromazine combination followed by 
Risperidone and Chlorpromazine combination. 
11) The patients who had taken anti-psychotic medications for more than 8 
years showed more preponderance for dry eye disease. Nearly 78% of patients had 
dry eye disease. 
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CONCLUSION 
32 out of 100 patients on anti-psychotic medications for more than 2 years had 
dry eye disease. Of the 200 eyes evaluated, 59 eyes were found to have dry eye 
disease. It was found to be more common in people between 41-60 years of age. 
Nearly 40% patients were in Grade 3 category of dry eye disease, which if not 
treated on time can lead to further progression and complication of disease. 
The patients who had taken anti-psychotic medications for more than 8 years, 
especially those who were on multi-drug regimen showed significant 
preponderance for dry eye disease. 
Inspite of the patient’s complaints of ocular discomfort , it is difficult to rely on 
it considering their general state of mind.  Our study however emphasizes on the 
need to give importance to patient’s symptoms, so that it can be detected earlier 
before it progresses . 
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                                                     PROFOMA 
Serial no: 
Name :  
Age: 
Sex: 
Occupation: 
Address : 
Ocular complaints: 
Associated  Systemic illness : 
Family history : 
Psychiatric disorder: 
Treatment: 
Duration of treatment: 
OCULAR  EXAMINATION                                                                                                     
      RE      LE 
Vision 
Eyelids and lashes 
Extra ocular movements 
Slit lamp examination 
Conjunctiva 
Cornea 
Anterior chamber 
Iris  
Pupil 
Lens 
 IOP 
TEAR FILM ANALYSIS: 
Tear film height: 
TBUT: 
Schirmers 1: 
Schirmers 2: 
Fluorescein staining: 
IMPRESSION: 
ADVICE: 
  
  
                                        KEY TO MASTER CHART 
M   - Male 
F   - Female 
SCH   - Schizophrenia 
PNOS  - Psychoses not otherwise specified 
HALO  - Haloperidol 
CPZ   - Chlorpromazine 
RISP   - Risperidone 
MG   - Milligrams 
OD   - once a day 
BD   - Twice a day 
TDS   - Thrice a day 
A   - Absent 
FBS   - Foreign body sensation 
IRR   - Irritation 
DIS   - Discomfort 
AB   - Absent 
P   - Present 
MIL   - Mild 
MOD   - Moderate 
SEV   - Severe 
MAR   - Marked 
DIF   - Diffuse 
N   - Normal 
RE   - Right eye 
LE   - Left eye 
 
 
NAME AGE SEX 
DIAGNO
SIS TREATMENT SYMPTOMS 
DURATIO
N(YEARS
) TBUT 
TEAR FILM 
HEIGHT SCHRIMER 1 SCHRIMER 2 
CONJUCTIVAL 
INJECTION 
CONJUCTIVAL 
STAINING 
CORNEAL 
STAINING 
SEVERITY OF 
DRY EYE 
RE LE RE LE RE LE RE LE RE LE RE LE RE LE RE LE 
MALA 28 F SCH HALO 1.5MG BD, CPZ 50MG OD A 2 N AB AB AB 8 2 3 0 A A A MOD MIL MAR 2 4 
KAMESH 35 M SCH HALO 5MG 1/2OD CPZ 100MG 2OD A 4 N N N N 35 35 28 28 A A A A A A N N 
RADHAKRISH
NAN 19 M SCH  HALO 5 MG BD CPZ 100MG BD A 4 N N N N 35 35 26 26 A A A A A A N N 
BABU 55 M SCH HALO 1.5MG OD A 5 N N N N 35 35 28 30 A A A A A A N N 
ANANDAN 49 M SCH CPZ 100MG 2OD  A 6 N N N N 13 25 9 20 A A A A A A N N 
THRUVAVAK
ARAN 30 M SCH HALO 1.5MG BD A 8 N N N N 25 15 20 11 A A A A A A N N 
BASKER 42 M SCH CPZ 100MG 3 OD, HALO 5MG BD A 6 N N N N 30 30 25 26 A A A A A A N N 
MOHD. ALI 47 M PNOS RISPER 2MG OD, A 7 N N N N 25 28 22 23 A A A A A A N N 
RAVI 37 M SCH HALO1.5MG TDS A 14 N N N N 30 30 26 26 A A A A A A N N 
PARVATHY 52 F SCH RISPER 2MG OD, CPZ 50MG OD FBS 10 
A
B AB AB AB 6 0 5 0 A A MIL SEV A DIF 2 4 
LAKSHMANA
N 55 M DD  HALO 5MG BD CPZ 100MG OD A 25 N N N N 10 10 6 6 A A A A A A N 2 
DHANALAKS
HMI 45 F SCH CPZ 50 MG OD A 7 N N AB AB 10 10 5 5 A A MIL MIL A MIL 2 2 
GEETHA 32 F SCH HALO 1.5MG BD A 7 N N N N 25 25 21 20 A A A A A A N N 
SHANTHI 38 F SCH RISP 2MG BD A 5 N N N N 35 35 30 28 A A A A A A N N 
SRINIVASAN 39 M SCH HALO5MG 3OD CPZ 100MG 2 TDS IRR 9 N N N AB 12 4 18 1 A A A MOD A MIL 1 3 
GANGADHAR
AN 43 M DD 
RISP 2MG OD, CPZ 100MG 2OD, HALO 
5MG OD A 11 N N AB AB 6 7 3 3 A A MIL MIL MIL MIL 2 2 
NALINI 28 F SCH HALO 1.5MG BD, CPZ 50MG OD A 12 
A
B AB AB AB 8 2 4 0 A A A MOD MIL MAR 2 3 
IKRAM  46 M SCH HALO 5MG 1/2OD CPZ 100MG 2OD A 3 N N N N 35 35 30 30 A A A A A A N N 
DEVENDRAN 51 M SCH HALO 5MG OD CPZ100MG OD A 11 N AB AB AB 9 5 5 2 A A A MIL A MIL 2 3 
SEKAR 30 M PNOS RISP 2MG OD, CPZ 100MG OD A 4 N N N N 18 25 14 21 A A A A A A N N 
RAMAN 40 M SCH HALO5MG 3OD CPZ 100MG 2 TDS A 9 N AB N AB 20 6 16 3 A A A MIL A A N 2 
IBRAHIM 64 M DD RISP 2MG OD  A 8 N N N N 35 35 30 28 A A A A A A N N 
DHANAM 38 F SCH CPZ 100MG OD  A 20 N N N N 25 25 20 19 A A A A A A N N 
POURNAMI 50 F SCH HALO 5MG OD, CPZ 50MG OD IRR 10 A AB AB AB 4 4 1 1 A A MIL MIL MIL MIL 3 3 
B 
RAMYA 18 F SCH RISP 2MG OD A 3 N N N N 10 10 6 7 A A A A A A 2 2 
SHANTHI 30 F SCH RISP 2MG BD FBS 11 
A
B AB AB AB 3 2 0 0 P P MIL MIL MIL MIL 3 4 
DAMODARAN 58 M SCH RISP 2MG OD  A 30 N N N N 30 35 28 30 A A A A A A N N 
GUNASEKARA
N 20 M SCH  HALO 5 MG BD CPZ 100MG BD A 5 N N N N 30 30 25 25 A A A A A A N N 
SUNDARI 21 F DD  HALO 5 MG BD CPZ 100MG BD A 6 N N N N 30 30 25 25 A A A A A A N N 
MUNNIAMMA
L 36 F SCH CPZ 100MG OD  A 21 N N N N 25 25 18 18 A A A A A A N N 
RAJA 45 M SCH RISPER 2MG OD, CPZ 50MG OD DIS 8 
A
B AB AB AB 5 1 2 0 A A MIL MOD MIL MAR 3 4 
YESHUDAS 40 M SCH CPZ 100MG OD  A 17 N N N N 22 22 18 19 A A A A A A N N 
MARI 46 M SCH 
RISP 2MG OD, CPZ 100MG 2OD, HALO 
5MG OD A 10 
A
B AB AB AB 6 6 5 4 A A MIL MIL MIL MIL 2 2 
VISHWA 35 M SCH CPZ 100MG OD  P 23 N N N N 30 25 25 21 A A A A A A N N 
VENKATESH 50 M SCH CPZ 100MG 2OD  A 8 N N N N 12 30 6 25 A A A A A A N N 
ANGAMMAL 20 F SCH RISP 2MG OD A 4 N N N N 35 35 30 30 A A A A A A N N 
BASKER 20 M SCH CPZ 100MG BD, HALO 5 MG BD A 4 N N N N 30 30 25 25 A A A A A A N N 
SAMPATH 47 M DD RISPER 2MG OD, CPZ 50MG OD FBS 9 
A
B AB AB AB 0 3 0 1 P P SEV MOD DIF DIF 4 3 
KUMARAN 48 M SCH CPZ 100MG 2OD  A 7 N N N N 28 13 20 6 A A A A A A N N 
RAJU 21 M SCH CPZ 100MG BD, HALO 5 MG BD A 5 N N N N 30 30 25 25 A A A A A A N N 
FATHIMA 51 F SCH HALO 5MG OD, CPZ 50MG OD IRR 11 
A
B AB AB AB 3 3 0 0 P P MIL MIL MIL MIL 3 3 
MUNISHVERA
L 35 M PNOS CPZ 100MG OD  A 17 N N N N 30 28 26 24 A A A A A A 3 3 
BABY 45 F SCH HALO 5MG BD, CPZ 50MG OD DIS 21 
A
B AB AB AB 5 6 3 3 A A MIL MIL MIL MIL 3 2 
LILY 35 F DD CPZ 100MG OD  A 17 N N N N 30 30 25 25 A A A A A A N N 
DURAI 56 M SCH RISP 2MG OD  A 28 N N N N 35 35 30 30 A A A A A A N N 
MOHD. 
SALEEM 20 M PNOS  HALO 5 MG BD CPZ 100MG BD A 5 N N N N 35 35 30 29 A A A A A A N N 
THANGAM 42 M SCH CPZ 100MG OD  A 19 N N N N 25 25 20 20 A A A A A A N N 
VISHWANATH 60 M SCH RISP 2MG OD  A 27 N N N N 35 35 30 29 A A A A A A N N 
AN 
THOMAS 50 M SCH CPZ 100MG 2OD  A 8 N N N N 18 25 14 20 A A A A A A N N 
KARTHICK 19 M PNOS HALO 1.5MG OD A 4 N N AB AB 9 8 4 5 A A MIL MIL A A 2 2 
LATHA 32 F SCH RISP 2MG OD, CPZ 100MG OD A 7 N N N N 23 25 17 18 A A A A A A N N 
DHARMADUR
AI 56 M SCH CPZ 100MG 2OD  A 8 N N N N 25 25 18 19 A A A A A A N N 
ANTONY 52 M DD CPZ 100MG 2OD  A 7 N N N N 18 18 13 13 A A A A A A N N 
KALYANI 46 F PNOS CPZ 100MG 2OD  A 9 N N N AB 25 10 18 5 A A A A A A N 2 
PALLAVI 49 F PNOS CPZ 100MG 2OD  A 8 N N N N 26 25 20 18 A A A A A A N N 
RAJKUMAR 68 M SCH RISP 2MG OD  A 10 N N N N 35 35 28 29 A A A A A A N N 
SARATH 56 M PNOS HALO 5MG BD, CPZ 50MG OD DIS 34 
A
B AB AB AB 4 5 3 4 A A MIL MIL MIL MIL 3 3 
MUNNUSAMM
Y 55 M DD CPZ 100MG 2OD  A 10 N N N N 30 25 25 22 A A A A A A N N 
DHANALAXMI 45 F SCH RISPER 2MG OD, A 9 N N N N 24 24 19 19 A A A A A A N N 
PRAKASH 28 M SCH RISP 2MG OD, CPZ 100MG OD A 6 N N N N 24 18 19 15 A A A A A A N N 
PRASANTH 26 M SCH HALO 1.5MG BD, CPZ 50MG OD IRR 8 
A
B AB AB AB 5 6 3 3 A A MIL MIL MIL MIL 3 2 
SUDHA 44 F SCH CPZ 50 MG OD A 7 N N N N 12 12 7 7 A A A A A A N N 
VALLI 43 F DD CPZ 50 MG OD A 7 N N AB AB 10 10 5 5 A A MIL MIL A A 2 2 
KUPPU 34 F SCH HALO 1.5MG BD A 9 N N N N 25 25 20 20 A A A A A A N N 
SAMY 28 M SCH RISP 2MG OD, CPZ 100MG OD A 5 N N N N 24 20 20 16 A A A A A A N N 
KUPPUSAMY 49 M SCH RISPER 2MG OD, A 8 N N N N 30 24 24 18 A A A A A A N N 
VEDEHI 30 F SCH HALO 1.5MG BD A 8 N N N N 25 25 20 20 A A A A A A N N 
KUMARI 53 F SCH HALO 5MG BD, CPZ 50MG OD 
BURNING 
SENSATION 17 
A
B AB AB AB 2 3 0 2 P P MOD MOD MAR MAR 4 3 
YELAMURUG
AN 45 M SCH CPZ 50 MG OD A 8 N N N N 13 13 8 8 A A A A A A N N 
VELAYUDHA
N 32 M SCH HALO 1.5MG BD A 9 N N N N 28 28 22 20 A A A A A A N N 
GURURAJ 30 M SCH RISP 2MG OD, CPZ 100MG OD A 4 N N N N 18 19 14 14 A A A A A A N N 
VEERASAMY 34 M DD HALO 1.5MG BD, CPZ 50MG OD IRR 10 N N AB AB 7 4 5 3 A A A MIL MIL MIL 2 3 
MANI 30 M SCH RISP 2MG OD, CPZ 100MG OD A 4 N N N N 18 25 4 4 A A A A A A N N 
MURUGAN 43 M SCH 
RISP 2MG OD, CPZ 100MG 2OD, HALO 
5MG OD A 11 N N N N 24 26 20 20 A A A A A A N N 
CHANDRA 52 F SCH HALO 1.5MG OD A 7 N N N N 28 28 22 23 A A A A A A N N 
RADHAKRISH
NAN 50 M SCH HALO 5MG OD CPZ100MG OD DIS 12 N AB AB AB 9 4 4 1 A A MIL MIL MIL MIL 2 3 
DANIEL 31 M SCH HALO 1.5MG BD A 6 N N N N 26 25 22 22 A A A A A A N N 
MESHA 29 F SCH RISP 2MG BD A 6 N N N N 35 35 30 30 A A A A A A N N 
SELUPATHY 32 M DD HALO 1.5MG BD A 10 N N N N 25 17 20 14 A A A A A A N N 
JASMINE 39 F SCH 
RISP 2MG OD, CPZ 100MG 2OD, HALO 
5MG OD A 9 
A
B AB AB AB 4 5 3 2 A A MIL MIL MIL MIL 3 3 
VENKATACH
ALAM 50 M SCH HALO 1.5MG OD A 5 N N N N 35 35 30 30 A A A A A A N N 
ARAVIND 25 M SCH HALO 1.5MG BD A 10 N N AB AB 7 8 4 4 A A A A A A 2 2 
RAJESH 31 M SCH HALO 1.5MG BD DIS 17 
A
B AB AB AB 3 7 1 4 A A MOD MIL MAR A 3 2 
YASMIN 33 F SCH HALO 1.5MG BD A 9 N N N N 30 25 25 21 A A A A A A N N 
MANIKANDA
N 49 M DD RISPER 2MG OD, CPZ 50MG OD A 11 
A
B AB AB AB 4 2 3 0 A A MIL MIL MIL MIL 3 3 
KRISHNAMUR
THY 56 M SCH HALO 1.5MG OD A 6 N N N N 28 30 24 25 A A A A A A N N 
VELARMUTH
U 50 M DD HALO 1.5MG OD A 5 N N N N 30 30 24 24 A A A A A A N N 
VELU 24 M SCH HALO 1.5MG BD A 8 N N N N 18 26 15 22 A A A A A A N N 
SOUNDARYA 49 F DD RISPER 2MG OD, A 8 N N N N 30 24 24 18 A A A A A A N N 
KALYANI 55 F SCH HALO 1.5MG OD A 6 N N N N 35 35 29 30 A A A A A A N N 
VAISHNAVI 28 F PNOS RISP 2MG BD A 6 N N N N 35 35 30 30 A A A A A A N N 
LOGANATHA
N 42 M SCH CPZ 100MG 3 OD, HALO 5MG BD A 6 N N N N 35 35 29 28 A A A A A A N N 
SAI 33 F SCH HALO 1.5MG BD A 8 N N N N 23 25 18 18 A A A A A A N N 
DURAI 24 M SCH HALO 1.5MG BD A 8 N N N N 18 26 15 22 A A A A A A N N 
GURUSAMY 57 M DD RISP 2MG OD  A 29 N N N N 35 35 30 30 A A A A A A N N 
SRINIVASAN 60 M SCH HALO 5MG BD, CPZ 50MG OD IRR 40 
A
B AB AB AB 4 6 2 3 P P MIL MIL MIL MIL 3 2 
KRISHNAAAM
AI 34 F SCH HALO 1.5MG BD A 9 N N N N 25 25 20 20 A A A A A A N N 
SYED 
MOHAMMED 25 M SCH HALO 1.5MG BD A 10 N N N N 35 35 30 30 A A A A A A N N 
RUKAMANI 49 F SCH HALO 5MG OD, CPZ 50MG OD IRR 9 
A
B AB AB AB 2 2 0 0 P P MOD MOD DIF  DIF 4 4 
  
  
